AU768720B2 - Aminopyrimidines as sorbitol dehydrogenase inhibitors - Google Patents

Aminopyrimidines as sorbitol dehydrogenase inhibitors Download PDF

Info

Publication number
AU768720B2
AU768720B2 AU31845/00A AU3184500A AU768720B2 AU 768720 B2 AU768720 B2 AU 768720B2 AU 31845/00 A AU31845/00 A AU 31845/00A AU 3184500 A AU3184500 A AU 3184500A AU 768720 B2 AU768720 B2 AU 768720B2
Authority
AU
Australia
Prior art keywords
alkyl
compound
pyrimidin
piperazin
optionally substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU31845/00A
Other languages
English (en)
Other versions
AU3184500A (en
Inventor
Margaret Yuhua Chu-Moyer
Jerry Anthony Murry
Banavara Lakshman Mylari
William James Zembrowski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Products Inc
Original Assignee
Pfizer Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc filed Critical Pfizer Products Inc
Publication of AU3184500A publication Critical patent/AU3184500A/en
Application granted granted Critical
Publication of AU768720B2 publication Critical patent/AU768720B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
    • C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
    • C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
    • C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
    • C04B35/632—Organic additives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C07D451/06—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Ceramic Engineering (AREA)
  • Manufacturing & Machinery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Structural Engineering (AREA)
  • Materials Engineering (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
AU31845/00A 1999-04-01 2000-03-16 Aminopyrimidines as sorbitol dehydrogenase inhibitors Ceased AU768720B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12743799P 1999-04-01 1999-04-01
US60/127437 1999-04-01
PCT/IB2000/000296 WO2000059510A1 (en) 1999-04-01 2000-03-16 Aminopyrimidines as sorbitol dehydrogenase inhibitors

Publications (2)

Publication Number Publication Date
AU3184500A AU3184500A (en) 2000-10-23
AU768720B2 true AU768720B2 (en) 2004-01-08

Family

ID=22430114

Family Applications (1)

Application Number Title Priority Date Filing Date
AU31845/00A Ceased AU768720B2 (en) 1999-04-01 2000-03-16 Aminopyrimidines as sorbitol dehydrogenase inhibitors

Country Status (41)

Country Link
US (5) US6414149B1 (enExample)
EP (1) EP1185275A1 (enExample)
JP (1) JP3581103B2 (enExample)
KR (1) KR20020005653A (enExample)
CN (1) CN1351497A (enExample)
AP (2) AP2005003199A0 (enExample)
AR (1) AR020562A1 (enExample)
AU (1) AU768720B2 (enExample)
BG (1) BG106038A (enExample)
BR (1) BR0009433A (enExample)
CA (1) CA2366858A1 (enExample)
CR (1) CR6471A (enExample)
CZ (1) CZ20013465A3 (enExample)
DZ (1) DZ3037A1 (enExample)
EA (1) EA004656B1 (enExample)
EE (1) EE200100509A (enExample)
GT (1) GT200000038A (enExample)
HK (1) HK1045461A1 (enExample)
HN (1) HN2000000040A (enExample)
HR (1) HRP20010716A2 (enExample)
HU (1) HUP0201011A3 (enExample)
ID (1) ID30489A (enExample)
IL (1) IL145364A0 (enExample)
IS (1) IS6076A (enExample)
MA (1) MA26727A1 (enExample)
MX (1) MXPA01009871A (enExample)
MY (1) MY136039A (enExample)
NO (1) NO20014642L (enExample)
NZ (1) NZ514144A (enExample)
OA (1) OA11856A (enExample)
PA (1) PA8493201A1 (enExample)
PE (1) PE20001601A1 (enExample)
PL (1) PL350884A1 (enExample)
SK (1) SK13532001A3 (enExample)
TN (1) TNSN00065A1 (enExample)
TR (1) TR200102810T2 (enExample)
UA (1) UA71951C2 (enExample)
UY (1) UY26089A1 (enExample)
WO (1) WO2000059510A1 (enExample)
YU (1) YU71101A (enExample)
ZA (1) ZA200108039B (enExample)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA004656B1 (ru) * 1999-04-01 2004-06-24 Пфайзер Продактс Инк. Аминопиримидины в качестве ингибиторов сорбитолдегидрогеназы
JP2004517053A (ja) * 2000-10-18 2004-06-10 ファイザー・プロダクツ・インク スタチン類とソルビトールデヒドロゲナーゼ阻害薬の併用
SE0003795D0 (sv) * 2000-10-20 2000-10-20 Astrazeneca Ab Pharmaceutically useful compounds
WO2002043762A2 (en) 2000-11-30 2002-06-06 Pfizer Products Inc. Combination of gaba agonists and sorbitol dehydrogenase inhibitors
CA2433090A1 (en) * 2000-12-27 2002-07-04 Kyowa Hakko Kogyo Co., Ltd. Dipeptidyl peptidase iv inhibitor
IL147696A0 (en) * 2001-01-25 2002-08-14 Pfizer Prod Inc Combination therapy
EP1247809A3 (en) 2001-03-30 2003-12-17 Pfizer Products Inc. Triazine compounds useful as sorbitol dehydrogenase inhibitors
EP1389189A2 (en) 2001-05-22 2004-02-18 Neurogen Corporation Melanin concentrating hormone receptor ligands: substituted 1-benzyl-4-aryl piperazine analogues
GB0127929D0 (en) * 2001-11-21 2002-01-16 Celltech R&D Ltd Chemical compounds
US7279470B2 (en) * 2001-12-14 2007-10-09 Novo Nordisk A/S Compounds and uses thereof for decreasing activity of hormone-sensitive lipase
US7015227B2 (en) 2002-06-21 2006-03-21 Cgi Pharmaceuticals, Inc. Certain amino-substituted monocycles as kinase modulators
US7582635B2 (en) 2002-12-24 2009-09-01 Purdue Pharma, L.P. Therapeutic agents useful for treating pain
MY150088A (en) 2003-05-19 2013-11-29 Irm Llc Immunosuppressant compounds and compositions
EP1644367B1 (en) * 2003-05-19 2015-10-14 Novartis AG Immunosuppressant compounds and compositions
WO2004111007A1 (en) * 2003-06-12 2004-12-23 Novo Nordisk A/S 1-aryl-4-(aryloxycarbonyl)-piperazine derivatives for use as inhibitors of hormone sensitive lipase
JP2007534624A (ja) * 2003-07-16 2007-11-29 ニューロジェン・コーポレーション ビアリールピペラジニル−ピリジン類縁体
TWI290140B (en) * 2003-08-25 2007-11-21 Schering Corp 2-Substituted benzimidazole derivatives as selective melanin concentrating hormone receptor antagonists for thr treatment of obesity and related disorders
JP5069907B2 (ja) * 2003-09-17 2012-11-07 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 縮合複素環式化合物
WO2005037284A1 (en) * 2003-10-15 2005-04-28 Pfizer Products Inc. Sorbitol dehydrogenase inhibitor and hypertensive agent combinations
WO2005047268A2 (en) * 2003-11-10 2005-05-26 X-Ceptor Therapeutics, Inc. Substituted pyrimidine compositions and methods of use
US7253168B2 (en) * 2004-04-07 2007-08-07 Neurogen Corporation Substituted 1-benzyl-4-substituted piperazine analogues
US20050239791A1 (en) * 2004-04-07 2005-10-27 Hutchison Alan J Substituted 1-heteroaryl-4-substituted piperazine and piperidine analogues
TW200609219A (en) * 2004-06-17 2006-03-16 Neurogen Corp Aryl-substituted piperazine derivatives
MY145822A (en) * 2004-08-13 2012-04-30 Neurogen Corp Substituted biaryl piperazinyl-pyridine analogues
GB0420831D0 (en) 2004-09-17 2004-10-20 Glaxo Group Ltd Novel compounds
US20060128710A1 (en) * 2004-12-09 2006-06-15 Chih-Hung Lee Antagonists to the vanilloid receptor subtype 1 (VR1) and uses thereof
AU2006215080B2 (en) 2005-02-17 2011-03-10 Astellas Pharma Inc. Pyridyl non-aromatic nitrogenated heterocyclic-1-carboxylate ester derivative
US7297700B2 (en) 2005-03-24 2007-11-20 Renovis, Inc. Bicycloheteroaryl compounds as P2X7 modulators and uses thereof
WO2006119451A1 (en) * 2005-05-04 2006-11-09 Vertex Pharmaceuticals Incorporated Pyrimidines and pyrazines useful as modulators of ion channels
EP1904491A2 (en) 2005-05-31 2008-04-02 Vertex Pharmaceuticals Incorporated Heterocycles useful as modulators of ion channels
US7598255B2 (en) 2005-08-04 2009-10-06 Janssen Pharmaceutica Nv Pyrimidine compounds as serotonin receptor modulators
BRPI0614397A2 (pt) 2005-08-04 2011-03-29 Janssen Pharmaceutica Nv compostos de pirimidina como moduladores de receptor de serotonina
CN101426860A (zh) * 2005-08-19 2009-05-06 伊兰医药品股份有限公司 γ-分泌酶的桥连N-环磺酰氨基抑制剂
CA2632027A1 (en) 2005-12-14 2007-06-21 Amgen Inc. Diaza heterocyclic sulfonamide derivatives and their uses
AU2007342531B2 (en) * 2006-12-20 2011-10-13 Merck Sharp & Dohme Corp. Bipiperidinyl compounds, compositions containing such compounds and methods of treatment
CA2685121A1 (en) 2007-04-27 2008-11-06 Purdue Pharma L.P. Therapeutic agents useful for treating pain
TWI362930B (en) 2007-04-27 2012-05-01 Purdue Pharma Lp Trpv1 antagonists and uses thereof
ES2380165T3 (es) * 2007-08-02 2012-05-09 Recordati Ireland Limited Nuevos compuestos heterocíclicos como antagonistas mGlu5
US8546572B2 (en) * 2008-03-31 2013-10-01 Sun Pharmaceutical Industries Limited Process for the preparation of morphinane analogues
US8759362B2 (en) * 2008-10-24 2014-06-24 Purdue Pharma L.P. Bicycloheteroaryl compounds and their use as TRPV1 ligands
US8703962B2 (en) * 2008-10-24 2014-04-22 Purdue Pharma L.P. Monocyclic compounds and their use as TRPV1 ligands
US8658648B2 (en) 2008-12-05 2014-02-25 Designmedix, Inc. Modified chloroquines with single ring moiety or fused ring moiety
US20100317630A1 (en) * 2009-02-04 2010-12-16 Recordati Ireland Limited Novel heterocyclic compounds as mglu5 antagonists
TWI482771B (zh) * 2009-05-04 2015-05-01 Du Pont 磺醯胺殺線蟲劑
CN101619063B (zh) * 2009-06-02 2011-08-10 华中师范大学 具有抗肿瘤活性的3,7,8-多取代吡啶并[4,3-d]嘧啶衍生物及制备
US20120028931A1 (en) * 2009-09-14 2012-02-02 Recordati Ireland Limited Heterocyclic m-glu5 antagonists
AR080375A1 (es) 2010-03-05 2012-04-04 Sanofi Aventis Procedimiento para la preparacion de 2-(cicloheximetil)-n-{2-[(2s)-1-metilpirrolidin-2-il] etil}-1,2,3,4-tetrahidroisoquinolina- 7-sulfonamida
DK2552920T3 (en) 2010-04-02 2017-06-12 Ogeda Sa UNKNOWN UNKNOWN NK-3 RECEPTOR SELECTIVE ANTAGONIST RELATIONS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN NK-3 RECEPTOR-MEDIUM DISORDERS
US10065960B2 (en) 2010-04-02 2018-09-04 Ogeda Sa NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disorders
JP5876423B2 (ja) 2010-06-22 2016-03-02 塩野義製薬株式会社 Ｔｒｐｖ１阻害活性を有する化合物とその使用
ES2624845T3 (es) * 2010-09-29 2017-07-17 Intervet International B.V. Compuestos de N-heteroarilo con unidad de puente cíclico para el tratamiento de enfermedades parasitarias
CN102572513A (zh) * 2010-12-13 2012-07-11 财团法人资讯工业策进会 网络协定电视互动系统、装置及其互动方法
MX354015B (es) 2011-06-22 2018-02-08 Shionogi & Co Antagonistas de trpv1 que incluyen sustituyentes dihidroxi y sus usos.
WO2013021276A1 (en) 2011-08-10 2013-02-14 Purdue Pharma L.P. Trpv1 antagonists including dihydroxy substituent and uses thereof
HRP20160396T1 (hr) * 2011-10-03 2016-07-15 Euroscreen S.A. Novi kiralni n-acil-5,6,7(8-susupstituirani)-tetrahidro-/1,2,4/triazolo/4,3-a/pirazini kao selektivni nk-3 receptor antagonisti, farmaceutski pripravak, i metode za upor
EP2822936B1 (en) 2012-03-07 2021-09-08 The McLean Hospital Corporation Aminoquinoline derivatives and uses thereof
CN103073506B (zh) * 2013-01-31 2015-03-11 京博农化科技股份有限公司 一种2-羟基-4,6-二甲基嘧啶盐酸盐的合成方法
WO2014141110A2 (en) * 2013-03-14 2014-09-18 Curadev Pharma Pvt. Ltd. Aminonitriles as kynurenine pathway inhibitors
CN105683192A (zh) * 2013-09-25 2016-06-15 沃泰克斯药物股份有限公司 用作par-2信号传导途径抑制剂的咪唑并哒嗪类
TWI651310B (zh) 2014-02-20 2019-02-21 日商日本煙草產業股份有限公司 三化合物及其醫藥用途
FR3022784B1 (fr) * 2014-06-26 2017-09-08 Ecole Normale Superieure Lyon Sondes moleculaires activables hydrosolubles, intermediaires pour leur synthese et procedes de detection associes
CA2961984C (en) 2014-09-25 2023-01-24 Ogeda Sa Novel chiral synthesis of n-acyl-(3-substituted)-(8-substituted)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines
JP2017529401A (ja) * 2014-09-26 2017-10-05 チャーンジョウ インシュヨン ファーマシューティカル カンパニー，リミティド Ｎｓ４ｂ阻害剤としてのベンゾフラン類似体
PE20170945A1 (es) 2014-11-03 2017-07-13 Bayer Pharma AG Derivados de feniltriazol sustituido con hidroxialquilo y sus usos
JP2017039714A (ja) 2015-08-17 2017-02-23 日本たばこ産業株式会社 ヒドロキシトリアジン化合物及びその医薬用途
TW201720822A (zh) 2015-08-28 2017-06-16 艾伯維股份有限公司 作為s1p調節劑之稠合雜環化合物
KR20180095564A (ko) * 2015-12-22 2018-08-27 지앙수 헨그루이 메디슨 컴퍼니 리미티드 벤조피페리딘 유도체, 이의 제조 방법 및 이의 의학적 용도
US9988367B2 (en) 2016-05-03 2018-06-05 Bayer Pharma Aktiengesellschaft Amide-substituted pyridinyltriazole derivatives and uses thereof
CN109071464A (zh) 2016-05-03 2018-12-21 拜耳制药股份公司 氧代烷基取代的苯基三唑衍生物及其用途
US11083720B2 (en) 2017-03-17 2021-08-10 Regents Of The University Of Colorado, A Body Corporate Indazole inhibitors of fructokinase (KHK) and methods of use in treating KHK-mediated disorders or diseases
IL272246B1 (en) 2017-07-28 2025-09-01 Applied Therapeutics Inc Derivatives of 2-(4-oxo/thioketone/azo-3-((substituted)benzo[d]thiazol-2-yl)methyl)- 3,4-dihydrothieno[3,4-d]pyridazin-1-yl)acetic acid for use as aldose reductase inhibitors in treating galactosemia or preventing complications associated with galactosemia
CN110872302B (zh) * 2018-08-31 2022-09-27 沈阳中化农药化工研发有限公司 含嘧啶的螺环类化合物及其用途
MX2021013511A (es) * 2019-05-07 2022-02-23 Univ Miami Tratamiento y deteccion de neuropatias heredadas y trastornos asociados.

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2010588A1 (en) * 1989-02-22 1990-08-22 Karl Geisen Substituted pyrimidine derivatives, their uses and a process for the preparation thereof
CA2048842A1 (en) * 1990-08-10 1992-02-11 Karl Geisen Substituted pyrimidine derivatives, a process for the preparation thereof and the use thereof as reagents
WO1994007867A1 (en) * 1992-09-28 1994-04-14 Pfizer Inc. Substituted pyrimidines for control of diabetic complications

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0791355T3 (da) * 1996-02-29 2002-06-17 Pfizer Fremgangsmåde til reduktion af vævsbeskadigelse forbundet med iskæmi
IT1285601B1 (it) 1996-03-08 1998-06-18 Bonfiglioli Riduttori Spa Riduttore angolare a piu' stadi
EA004656B1 (ru) * 1999-04-01 2004-06-24 Пфайзер Продактс Инк. Аминопиримидины в качестве ингибиторов сорбитолдегидрогеназы

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2010588A1 (en) * 1989-02-22 1990-08-22 Karl Geisen Substituted pyrimidine derivatives, their uses and a process for the preparation thereof
CA2048842A1 (en) * 1990-08-10 1992-02-11 Karl Geisen Substituted pyrimidine derivatives, a process for the preparation thereof and the use thereof as reagents
WO1994007867A1 (en) * 1992-09-28 1994-04-14 Pfizer Inc. Substituted pyrimidines for control of diabetic complications

Also Published As

Publication number Publication date
CZ20013465A3 (cs) 2002-10-16
UA71951C2 (en) 2005-01-17
UY26089A1 (es) 2000-10-31
EE200100509A (et) 2002-12-16
PA8493201A1 (es) 2002-07-30
CR6471A (es) 2003-11-25
AP2005003199A0 (en) 2005-03-31
US6936600B2 (en) 2005-08-30
HUP0201011A3 (en) 2003-11-28
ZA200108039B (en) 2003-07-22
PE20001601A1 (es) 2001-01-25
BR0009433A (pt) 2002-01-15
AR020562A1 (es) 2002-05-15
CN1351497A (zh) 2002-05-29
HK1045461A1 (zh) 2002-11-29
IL145364A0 (en) 2002-06-30
SK13532001A3 (sk) 2003-02-04
YU71101A (sh) 2004-07-15
MXPA01009871A (es) 2002-04-24
GT200000038A (es) 2001-09-22
BG106038A (en) 2002-06-28
EA200100933A1 (ru) 2002-04-25
HRP20010716A2 (en) 2002-12-31
JP3581103B2 (ja) 2004-10-27
US6660740B1 (en) 2003-12-09
HUP0201011A2 (en) 2002-08-28
NO20014642D0 (no) 2001-09-25
DZ3037A1 (fr) 2004-03-27
MY136039A (en) 2008-08-29
TNSN00065A1 (fr) 2005-11-10
NO20014642L (no) 2001-11-28
EP1185275A1 (en) 2002-03-13
CA2366858A1 (en) 2000-10-12
US6414149B1 (en) 2002-07-02
WO2000059510A1 (en) 2000-10-12
MA26727A1 (fr) 2004-12-20
PL350884A1 (en) 2003-02-10
EA004656B1 (ru) 2004-06-24
US20040077671A1 (en) 2004-04-22
IS6076A (is) 2001-09-18
AP2001002281A0 (en) 2001-09-30
TR200102810T2 (tr) 2002-01-21
HN2000000040A (es) 2001-02-02
AU3184500A (en) 2000-10-23
OA11856A (en) 2006-03-03
JP2002541109A (ja) 2002-12-03
US6602875B2 (en) 2003-08-05
KR20020005653A (ko) 2002-01-17
NZ514144A (en) 2001-09-28
US20030065179A1 (en) 2003-04-03
ID30489A (id) 2001-12-13
US20050020578A1 (en) 2005-01-27
US6869943B2 (en) 2005-03-22

Similar Documents

Publication Publication Date Title
AU768720B2 (en) Aminopyrimidines as sorbitol dehydrogenase inhibitors
CN114269735B (zh) 二氢或四氢喹唑啉类化合物及其中间体、制备方法和应用
US9855269B2 (en) Aminoquinazoline and pyridopyrimidine derivatives
AU2004228352B2 (en) Aminopyrimidine derivatives and their medical use
EP4051384A1 (en) Pyridazinones as parp7 inhibitors
US20100105674A1 (en) Chemical Compounds
US20100113445A1 (en) Chemical Compounds
AU2007264791A1 (en) Derivatives of ureas of piperidine or pyrrolidine, their preparation and their therapeutical use
CA2484282A1 (en) Pyrimidine derivatives intermediates for producing aminopyrimidines as sorbitol dehydrogenase inhibitors
WO2024227104A1 (en) Bifunctional compounds for degrading braf via ubiquitin proteosome pathway
HK1122558A (en) Benzimidazoles useful as inhibitors of protein kinases

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)